Preskočiť na obsah
CertaPeptides
Späť na všetky články
Peptide Guides9 min čítaniaMarch 29, 2026

Peptide Half-Life Chart: 35+ Research Peptides Compared (2026)

Skontrolovala: Anca Boboc, CertaPeptides

Peptide Half-Life Chart: 35+ Research Peptides Compared (2026)

Finding peptide half-life data usually means digging through a dozen Reddit threads and hoping someone cited an actual study. This is the consolidated reference — 35+ research peptides with half-lives, routes, and sources in one table.

A quick note on data quality: some peptides have published pharmacokinetic studies with precise half-life measurements in humans. Others have only animal data or community-estimated values. The table marks which is which so you know what you’re working with.

What half-life means (and what it doesn’t)

Elimination half-life is the time it takes for plasma concentration to drop by 50%. After about 4-5 half-lives, the compound is effectively cleared.

Half-life is NOT the same as duration of action. BPC-157 has a very short half-life (~minutes IV), but its downstream effects on gene expression and signaling pathways persist much longer. Semaglutide’s 7-day half-life aligns well with its duration of action because it works through sustained receptor occupancy. Different mechanisms, different relationships.

Factors that affect half-life: molecular weight (larger = generally longer), modifications (fatty acid acylation, PEGylation, DAC conjugation), route of administration (IV is fastest clearance, subQ creates a depot), and protein binding (albumin binding dramatically extends half-life).

Complete peptide half-life reference table

Peptide Half-Life Route Category Data Source
GLP-1 Receptor Agonists
Semaglutide ~168 hours (7 days) SubQ / Oral GLP-1 agonist Published PK (FDA label)
Tirzepatide ~120 hours (5 days) SubQ GIP/GLP-1 dual agonist Published PK (Coskun et al., 2018, PMID: 30473097)
Retatrutide ~144 hours (6 days) SubQ GIP/GLP-1/GCGR triple agonist Published PK (Urva et al., 2022, PMID: 36354040)
Exenatide ~2.4 hours SubQ GLP-1 agonist Published PK (FDA label)
Liraglutide ~13 hours SubQ GLP-1 agonist Published PK (FDA label)
Cagrilintide ~7 days SubQ Amylin analog Published PK (Enebo et al., 2021, PMID: 33894838)
Growth Hormone Secretagogues
CJC-1295 DAC ~8 days SubQ GHRH analog (DAC-conjugated) Published PK (Teichman et al., 2006, PMID: 16352683)
CJC-1295 (no DAC) ~30 minutes SubQ GHRH analog Published PK (Teichman et al., 2006)
Ipamorelin ~2 hours SubQ / IV Ghrelin mimetic Published PK (Raun et al., 1998, PMID: 9849822)
GHRP-2 ~15-25 minutes SubQ / IV Ghrelin mimetic Published PK (Bowers et al., 1991)
GHRP-6 ~15-20 minutes SubQ / IV Ghrelin mimetic Published PK (Bowers, 1998)
MK-677 (Ibutamoren) ~4-6 hours Oral GH secretagogue (non-peptide) Published PK (Nass et al., 2008, PMID: 18981485)
Sermorelin ~10-20 minutes SubQ / IV GHRH analog Published PK (FDA label)
Hexarelin ~60 minutes SubQ / IV Ghrelin mimetic Published PK
Healing & Recovery Peptides
BPC-157 ~2 min (IV), est. 4-6 hr (subQ depot) SubQ / Oral Gastric pentadecapeptide Animal PK data (estimated from detection windows)
TB-500 Est. 2-4 hours SubQ Tβ4 fragment Estimated (limited published PK)
GHK-Cu Est. 30-60 minutes SubQ / Topical Copper tripeptide Estimated (Pickart, 2008)
Thymosin Beta-4 (full) Est. 1-2 hours SubQ / IV Actin-sequestering protein Estimated from clinical studies
KPV Est. 20-30 minutes SubQ / Oral α-MSH fragment Estimated
Peptides
Selank ~30 sec – 3 min (native) / longer for analogs Intranasal / SubQ Tuftsin analog Published PK (Zozulia et al., 2008)
Semax ~30 sec – 3 min (native) Intranasal ACTH 4-7 analog Published PK (Russian literature)
Dihexa Est. 2-4 hours SubQ / Oral (proposed) HGF mimetic Estimated from animal studies
DSIP ~15-30 minutes IV / SubQ Nonapeptide Published PK (Kafi et al., 1979)
Immune & Anti-Inflammatory
Thymosin Alpha-1 (TA1) <3 hours SubQ Thymic peptide Published PK (Rost et al., 1999, PMID: 10027483)
LL-37 Est. 30-60 minutes SubQ / Topical Cathelicidin Estimated (susceptible to serum proteases)
Anti-Aging & Longevity
Epitalon Est. 2-3 hours SubQ / IV Tetrapeptide (Ala-Glu-Asp-Gly) Estimated from Russian clinical studies (Khavinson)
MOTS-c Est. 4-8 hours SubQ Mitochondrial-derived peptide Estimated from animal PK data
NAD+ (IV infusion) ~30-45 minutes (plasma) IV Coenzyme (not a peptide) Published PK (limited human data)
Melanocortin Peptides
Melanotan II Est. 60 minutes SubQ MC1R/MC4R agonist Estimated
PT-141 (Bremelanotide) ~120 minutes (2 hours) SubQ MC3R/MC4R agonist Published PK (FDA label, 2019)
Metabolic & Other
AOD-9604 Est. 30-60 minutes SubQ / Oral GH fragment (176-191) Estimated from Phase 2 studies
Oxytocin ~3-5 minutes (IV) IV / Intranasal Nonapeptide hormone Published PK (FDA label)
Insulin (regular) ~5-8 minutes (IV) SubQ / IV 51-aa hormone Published PK (FDA label)

Key: “Est.” = estimated from animal data, detection windows, or community-reported values. Not from published human PK studies. “Published PK” = data from peer-reviewed human pharmacokinetic studies or FDA/EMA drug labels.

The DAC difference: why CJC-1295 spans minutes to days

The most dramatic half-life difference in this table is CJC-1295 without DAC (~30 minutes) versus CJC-1295 with DAC (~8 days). Same peptide, 384x difference in half-life. How?

DAC (Drug Affinity Complex) is a reactive chemical group that covalently binds to serum albumin after injection. Once bound, the CJC-1295 molecule rides along with albumin — which has its own half-life of ~19 days in humans. The peptide effectively borrows albumin’s longevity.

Teichman et al. (2006) demonstrated that a single subcutaneous dose of CJC-1295 DAC produced sustained GH elevation for 6-8 days, with IGF-1 remaining elevated for 9-11 days (PMID: 16352683). Without DAC, the same peptide is cleared in under an hour.

This is the same principle (albumin binding) that gives semaglutide and tirzepatide their long half-lives — they use fatty acid acylation instead of covalent DAC bonding, but the mechanism is similar: hitch a ride on albumin to extend circulation time. For a deeper dive into how these molecular modifications work, see our GLP-1 pharmacokinetics guide.

GLP-1 agonist half-lives: why they dominate

The three GLP-1 agonists at the top of the table (semaglutide, tirzepatide, retatrutide) have half-lives measured in days while most peptides are measured in minutes to hours. This is entirely due to engineering.

Native GLP-1 has a half-life of ~2 minutes — it’s rapidly degraded by DPP-4 enzymes. The research compounds achieve 5-7 day half-lives through two modifications: DPP-4-resistant amino acid substitutions (preventing enzymatic degradation) and fatty acid acylation that promotes albumin binding (preventing renal clearance).

They reach steady state in 4-5 weeks. If you’re measuring acute pharmacological effects, you need to account for this long wash-in period.

Short-acting peptides: why minutes doesn’t mean ineffective

BPC-157’s ~2-minute IV half-life seems absurdly short. But half-life and efficacy aren’t the same thing. BPC-157’s reported effects have been linked to the NO system and to FAK-paxillin pathway activation (Sikiric et al., 2016, PMID: 27138887).

The peptide is the trigger, not the sustained effector.

Reconstituted solutions should be stored at 2-8°C and used within 28 days to maintain potency. Use our reconstitution calculator to work out concentrations, and check the peptide storage guide for detailed handling instructions.

How half-life affects storage stability

There’s a loose correlation between half-life and solution stability, but it’s not direct. Short half-life usually means the molecule is susceptible to enzymatic or chemical degradation — and those same vulnerabilities apply in the vial. Peptides with multiple basic residues (Arg, Lys) or free thiol groups (Cys) tend to degrade faster in solution.

General rules: lyophilized peptides at -20°C are stable for 6-24 months. Reconstituted peptides at 2-8°C last 21-28 days. Room temperature reconstituted peptides can lose significant activity within days. The shorter the half-life in vivo, the more critical proper storage becomes — because the same molecular vulnerabilities that cause rapid clearance also cause rapid degradation.

Frequently asked questions

What peptide has the longest half-life?

CJC-1295 with DAC at approximately 8 days, followed by semaglutide at ~7 days and cagrilintide at ~7 days. All three achieve long half-lives through albumin binding — DAC via covalent bonding, the others via fatty acid acylation. Without these modifications, native GLP-1 and native GHRH both have half-lives under 5 minutes.

What role does half-life play in experimental sampling design?

Half-life is one input into experimental sampling design but does not by itself determine it. BPC-157 (~2-minute half-life) is cleared rapidly; its reported effects are attributed to triggering downstream cascades rather than sustained receptor occupancy. The relationship between half-life and exposure depends on the mechanism of action.

Why is CJC-1295 DAC half-life so much longer than CJC-1295 without DAC?

The Drug Affinity Complex (DAC) covalently bonds to serum albumin after injection. Albumin has a ~19-day half-life in humans, so the peptide-albumin complex persists in circulation for days instead of minutes. Without DAC, CJC-1295 is a ~3 kDa peptide that’s rapidly cleared by the kidneys — below the ~60 kDa glomerular filtration threshold. With DAC, it becomes part of a ~70 kDa albumin complex that’s too large for renal clearance.

Peptide half-lives range from seconds (Selank, Semax) to 8 days (CJC-1295 DAC). GLP-1 agonists: semaglutide ~7 days, tirzepatide ~5 days, retatrutide ~6 days — all via albumin binding. GH secretagogues: ipamorelin ~2 hours, GHRP-2/6 ~15-25 minutes, MK-677 ~5 hours. Healing peptides: BPC-157 ~2 min IV (downstream effects persist), TB-500 est. 2-4 hours. Short half-life does not mean low activity in a model — mechanism of action matters as much as clearance.

Limitations of this reference

  • Many research peptides lack published human pharmacokinetic data. Values marked “Est.” are derived from animal studies or community reports and should be treated as approximations.
  • Half-life varies by route of administration, individual metabolism, and co-administered compounds. Values shown are typical for the most common research route.
  • This chart does not constitute dosing guidance. Research protocol design should reference primary literature for the specific compound and application.

References

  1. Lau J, et al. “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.” J Med Chem. 2015;58(18):7370-7380. PMID: 26308095
  2. Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295.” JCEM. 2006;91(3):799-805. PMID: 16352683
  3. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
  4. Nass R, et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
  5. Sikiric P, et al. “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications.” Curr Neuropharmacol. 2016;14(8):857-865. PMID: 27138887
  6. Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996;58(20):1777-1784. PMID: 8637402

All compounds discussed are for laboratory and educational research purposes only. Not for human consumption.

Overte pred výskumom

Stránky produktov uvádzajú špecifikáciu na úrovni triedy, ak je nejaká evidovaná, a vybrané šarže majú nezávislý COA tretej strany.

Ste pripravení začať svoj výskum?

Stránky produktov uvádzajú špecifikáciu na úrovni triedy, ak je nejaká evidovaná; vybrané šarže majú nezávislý COA tretej strany. Zadajte kód z etikety vašej liekovky na našej overovacej stránke. Ak vyhľadanie kódu nič nenájde, pošlite nám tento kód e-mailom.

Odporučte výskumníka

Povedzte o nás kolegovi výskumníkovi

Poskytnite zľavu 15 % a získajte späť 10 % z prvej objednávky, ktorú vytvorí.